☆ 4.6 Article

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Lancet Respiratory Medicine (2020)

Get Full Text
Add to Collection

Journal

Lancet Respiratory Medicine
Volume -, Issue -, Pages -

Publisher

Elsevier BV
DOI: 10.1016/s2213-2600(19)30471-0

Keywords

-

Categories

Critical Care Medicine

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.